Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
While initial therapies have become highly effective with introduction of lenalidomide and bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect stem cells for future transplant. Given its increasing use as initial therapy, we examined if lenalidomide had any impact on the ability to collect peripheral blood stem cells (PBSC). We studied the entire cohort of patients with myeloma undergoing PBSC mobilization at our institution during a 5-year period, comparing the results between patients receiving different initial therapies. Among those mobilized with granulocyte-colony stimulating factor (G-CSF) alone, there was a significant decrease in total CD34(+) cells collected (P<0.001), average daily collection (P<0.001), day 1 collection (P<0.001) and increased number of aphereses (P=0.004) in patients treated with lenalidomide compared to those receiving dexamethasone, thalidomide-dexamethasone or VAD. A similar trend was seen in those mobilized with chemotherapy and G-CSF. A trend was seen towards decreased PBSC yield with increasing duration of lenalidomide therapy as well as increasing age (P=0.002). There was no effect on quality of PBSC collected based on similar engraftment across all groups. We recommend collection of PBSC within 6 months of initiation of therapy with lenalidomide containing regimens to minimize the risk of mobilization failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stem cell collection with granulocyte stimulating factor (G-CSF) alone may be impaired when lenalidomide is used as induction therapy.112”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [112]
In the citing paper
“This issue can often be overcome using high-dose cyclophosphamide or the CXCR4 antagonist plerixafor125.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [125]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“dtd"[ ]> Introduction High-dose therapy and autologous stem cell transplantation has been an important part of myeloma therapy ever since the initial randomized trials demonstrated a survival benefit for the procedure compared to conventional chemotherapy”
BackgroundSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · cited 1×
“11 Recent advances in the field, including the potential impact of tandem stem cell transplant and introduction of very effective agents such as bortezomib and lenalidomide have changed the landscape of treatment of myeloma”
BackgroundRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Self-citationCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citationProteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citation
Cited by
Items 301–351 of 351
Sheth, V., Jain, R., Gore, A. A., Ghanekar, A., & Saikia, T. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_46_19 · Cited by 1
VI. Standard Treatment for Multiple Myeloma
Ito, S., & Takano, M. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.1238 · Cited by 1
Recommendations on the management of multiple myeloma in 2020
Vekemans, M., Doyen, C., Caers, J., Wu, K., Kentos, A., Mineur, P., Michaux, L., Delforge, M., & Meuleman, N. (2020) · Acta Clinica Belgica · doi:10.1080/17843286.2020.1860411 · Cited by 2
“In this case, apheresis should not be performed beyond 4 cycles and may require the use of cyclophosphamide or plerixafor [53].”
BackgroundTREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA
Rajkumar, S. V., & Kyle, R. A. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.003 · Cited by 1
Self-citationFrom VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?
Parmar, H. V., Vesole, D. H., & Biran, N. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000522 · Cited by 1
“Significant exposure to lenalidomide-based therapy can be associated with decreased stem cell mobilization yield, particularly in patients with advanced age.(36,37) This limitation, however, can be overcome with the use of plerixafor in combination with granulocyte colony-stimulating factor.”
BackgroundImpact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients
Camilleri, M., McGrath, T., Wilson, W., Ings, S. J., Horder, J., Newrick, F., Sive, J. I., Papanikolaou, X. D., Popat, R., Kyriakou, C. A., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1941930 · Cited by 1
İltar, U., Ataş, Ü., VURAL, E. T., Alhan, F. N., Yücel, O. K., Salim, O., & Ündar, L. (2022) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2022.103351 · Cited by 1
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
Liberati, A. M., Vitolo, U., Palumbo, A., & Cortelezzi, A. (2013) · Advances in Hematology · doi:10.1155/2013/812605 · Cited by 1
Stem Cell Mobılızatıon in Multıple Myeloma
Mine, U., & Demirer, T. (2012) · InTech eBooks · doi:10.5772/30794
From cell biology to therapy: lenalidomide in untreated multiple myeloma
Palumbo, A. P., Falco, P., Gay, F., Magarotto, V., Patriarca, F. F., Nozzoli, C., & Boccadoro, M. (2009) · Hematology Meeting Reports · doi:10.4081/hmr.v2i5.744
Rajkumar, S. V., & Hayman, S. R. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781926.010
Self-citationExperience with Plerixafor in Poor Mobilizers
Roberts, C. H., & McCarty, J. M. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1960-0_15
Früehauf, S., & Tricot, G. J. K. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1960-0_9
Novel therapeutic concepts in multiple myeloma
Drach, J. W. (2009) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-009-0096-8
“Optimal use of lenalidomide plus dexamethasone combinations as induction treatment prior to ASCT still needs to be defined, because lenalidomide has been found to result in substantially reduced stem cell yield [ 17 , 18].”
BackgroundTHE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA
Schots, R., Delforge, M., André, M. P. E., Bries, G., Caers, J., Demuynck, H., Prijck, B. D., Samblanx, H. D., Kentos, A., Meuleman, N., et al. (2010) · Acta Clinica Belgica · doi:10.1179/acb.2010.055
“Prolonged treatment with lenalidomide may reduce mobilization effi ciency (49,50) so that cyclophosphamide may be required for stem cell mobilization (51).”
BackgroundPeripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma
Ria, R. (2014) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000226
Buadi, F. K., Hogan, W. J., Gertz, M. A., Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., & Hayman, S. R. (2012)
Self-citationPromoting quality of life for patients with myeloma
Dowling, M., Kelly, M., & Meenaghan, T. (2013) · Cancer Nursing Practice · doi:10.7748/cnp2013.10.12.8.30.e994
Rajkumar, S. V., Sonneveld, P., Sezer, O., Vesole, D. H., Cavo, M., Einsele, H., Richardson, P. G. G., Ludwig, H., Bergsagel, P. L., Bladé, J., et al. (2009)
Self-citationCurrent & Emerging Therapeutics for Multiple Myeloma
Raje, N. S., & Jagannath, S. (2013) · doi:10.2217/9781780842288
Proteasome inhibitors: A rational for clinical use in the treatment of multiple myeloma
Petković, I., Pejčić, I., & Vrbić, S. (2016) · Racionalna terapija · doi:10.5937/racter8-10447
Prunier, E., Caillot, D., Legouge, C., Limat, S., Hélias, P., Fontan, J., Heczcko, M., Brion, A., Ferrant, E., Delaby, P., et al. (2015) · Journal of Hematology and Oncology Research · doi:10.14302/issn.2372-6601.jhor-14-493
“For example, a previous treatment with lenalidomide could be an important factor leading to high risk of mobilization failure.(36-37)”
Wells, J. C. (2015) · UWE Research Repository (UWE Bristol)
Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
Chakraborty, R., & Gertz, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_28
Self-citationSanto, L., & Raje, N. S. (2013) · doi:10.2217/ebo.13.202
Huelva, F. J. C., Ríos, E., Rivas, M. A. A., Arredondo, J. J. R., Muñoz, A. A., Bailén, A., Zamudio, J. L., Ramírez, G., & Jurado, A. F. (2018) · Hematology and Leukemia · doi:10.7243/2052-434x-6-4
Current standard treatment of myeloma
Powles, R., & Meghani, A. (2013) · doi:10.2217/ebo.13.274
Patır, P., Soyer, N., Durusoy, R., Şahin, F., Saydam, G., Töbü, M., Tombuloğlu, M., & Vural, F. (2017) · LLM Dergi · doi:10.5578/llm.54152
Mobilization Strategies: HPC(A) Collections for Autologous Hematopoietic Cell Transplants
Worel, N. (2019) · Advances and controversies in hematopoietic transplantation and cell therapy · doi:10.1007/978-3-319-55131-9_5
Therapeutic Advances in the Management of Smoldering Myeloma
Khan, R., Zahid, U., Kollu, V. S., Jahan, N., McBride, A., Tricot, G. J. K., & Anwer, F. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001034
Evaluation of mobilization efficacy with an extended interval following plerixafor administration
Stump, S. E., Trepte, M., Shaw, J. R., Grgic, T., Ptachcinski, J. R., Sharf, A., Riches, M., Shea, T. C., Park, Y. A., & Alexander, M. D. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219900909
“Among patients with MM included in this study, 23% had received 6 cycles of therapy with immunomodulatory agents, which has been associated with lower total CD34þ yield and increased number of aphereses.(19,20) Thus, our study includes representation of a population at risk for poor mobilization.”
BackgroundMarumo, A., Yamaguchi, H., Hirakawa, T., Inai, K., Onai, D., Omori, I., Yamanaka, S., Fujiwara, Y., Sakaguchi, M., Wakita, S., et al. (2020) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2021_88-104
Badarkhe, G., & Naik, R. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_154_19
Current Awareness in Hematological Oncology
(2008) · Hematological Oncology · doi:10.1002/hon.831
Is There Improvement in the Care for Patients With Multiple Myeloma?
(2015) · International Journal of Science and Research (IJSR) · doi:10.21275/v4i11.nov151442
“Several randomized studies analyzed the effect of Lenalidomide as induction treatment in MM (17).”
BackgroundBatsukh, K., Norov, O., Jigjidkhorloo, N., Boldbaatar, A., Tungalag, S., Gunchin, B., & Tsogbadrakh, O. (2017) · Central Asian Journal of Medical Sciences · doi:10.24079/cajms.2017.06.011
Merz, A. M. A., Merz, M., Hillengaß, J., Holstein, S. A., & McCarthy, P. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_18
Kumar, S. K., & Gertz, M. A. (2007) · Leukemia · doi:10.1038/sj.leu.2405036
Self-citationYee, A. J., Hideshima, T., Raje, N. S., & Anderson, K. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122.pub2
de Charry, F., Konopacki, J., Bugier, S., Foissaud, V., Sloma, I., Malfuson, J., & Arnautou, P. (2023) · Leukemia Research Reports · doi:10.1016/j.lrr.2023.100366
Sadri, S., Hindilerden, İ. Y., Mutlu, Y. G., Tiryaki, T. O., Gemici, A. İ., Beköz, H. S., Sevindik, Ö. G., Hindilerden, F., Beşışık, S. K., Nalçacı, M., et al. (2023) · The European Research Journal · doi:10.18621/eurj.1231251 · Cited by 1
Sim, S., Quach, H., Pham, T. T., Smooker, V., & Filshie, R. (2023) · Internal Medicine Journal · doi:10.1111/imj.16170
Kostroma, I. I., Chubukina, Z. V., Yudina, V., Романенко, Н. А., Stepchenkova, E. I., Бессмельцев, С. С., Sidorkevich, S. V., & Грицаев, С. В. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-1-43-49
Does immunohistochemical staining predict mobilization success in multiple myeloma patients?
Karadağ, F. K., Aysın, M., Soyer, N., Güneş, A. E., Bozer, D. S., Demir, D., Arslan, A., Şahin, F., Töbü, M., Saydam, G., et al. (2024) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2024.104004
Peña, O. D. R., Villamizar, L., Charry, P. A., Camargo, T., Pedraza, E., & Cid, J. (2025) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2025.104244
Zhu, Z., Li, X., Chen, X., Yuan, X., Lin, T., & Li, N. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102075
Evaluation of our real-life data in multiple myeloma patients in the light of current treatments.
Burkut, S. İ. (2019) · Çukurova University Institutional Repository
Swain, R. N., Lad, D. P., Wadhera, S., Jandial, A., Singh, C., Jain, A., Prakash, G., Khadwal, A., Sachdeva, M. U., & Malhotra, P. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2651948
“Lenalidomide, a key component of current triplet and quadruplet induction regimens, has been associated with reduced mobilization efficiency when administered for prolonged durations [7,8].”
Novellis, D. D., Fontana, R., Rizzo, M., Carobene, A., Morini, D., Serio, B., Guariglia, R., Luponio, S., Langella, M., Verdesca, F., et al. (2026) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2026.104430
Zhang, Y., Qin, X.-Y., Cao, C., Luo, Z., Zhang, Y., Zeng, H., Deng, J.-C., & Luo, Y. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101263
Lin, Y., Aiello, J., Avigan, D., Berdeja, J. G., Biru, Y., Chari, A., Christenson, L. H., Costello, C. L., Garfall, A. L., Green, D. J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016142
Self-citation
Metadata
- Authors
- Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., & Gertz, M. A.
- Affiliations
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Kumar, S
- ORCID
- Venue
- Leukemia
- Published
- 2007-06-21
- Volume
- 21
- Issue
- 9
- Pages
- 2035-2042
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2036985459
- Semantic Scholar
- 831eb40600d3fcbfc29f2b9cc655e7c78f420e1f
- Cited by
- 351
- References
- 35
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 18 · 2019: 16 · 2018: 9 · 2017: 17 · 2016: 15 · 2015: 23 · 2014: 15 · 2013: 29 · 2012: 27
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- lenalidomide, peripheral blood stem cell mobilization, stem cell engraftment, multiple myeloma, newly diagnosed multiple myeloma, granulocyte colony-stimulating factor, CD34+ cell yield, apheresis, VAD chemotherapy, bortezomib, mobilization failure
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Vincristine, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Hormonal, Hematopoietic Stem Cell Mobilization, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.